Clinical & Scientific

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

A biotech firm's non-hallucinogenic drug just passed a key safety test. Could this novel approach finally disrupt the challenging world of alcohol use disorder?

A new patent gives Cognition Therapeutics’ lead drug candidate protection until 2045. Here’s why this strategic move is about more than just IP.

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.

Brixton Metals unveils stunning high-grade silver at its historic Langis Project, pushing aggressively toward a maiden resource and commercial viability.

Crescom's AI is being tested at Mass General Brigham, aiming to ease radiologist burnout and establish a critical foothold in the competitive US MedTech market.

A new surgical method called SMART, developed at Delray Medical Center, uses biological scaffolds to overcome the failure of sutures in critical muscle injuries.

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

Tiny biotech HCW Biologics reports promising early data for its alopecia drug. But with a small sample size and big pharma rivals, is this a true breakthrough?

Newcore Gold's latest deep drilling at its Enchi project in Ghana extends high-grade gold zones, signaling major resource growth ahead of a pivotal study.

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

With a major debt financing, French biotech Inventiva is funded through a pivotal Phase 3 trial for its MASH drug, highlighting a strategic shift in biotech funding.

With its Madsen Mine now in production, West Red Lake Gold turns to a past-producing legend, signaling a methodical strategy to build a multi-asset gold empire.

Light AI's smartphone diagnostic tool enters a crucial New Zealand study, but can its innovative tech overcome financial pressures and regulatory hurdles?

Nordicus Partners reveals promising data for gum disease and oral lesions, betting its future on a unique Nordic acquisition strategy and a Nasdaq uplisting.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.